Monarch Capital Management’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$12.3M Buy
49,047
+275
+0.6% +$59.2K 2.83% 8
2026
Q1
$10.6M Sell
48,772
-820
-2% -$182K 2.6% 11
2025
Q4
$11.3M Sell
49,592
-882
-2% -$201K 2.79% 9
2025
Q3
$11.7M Sell
50,474
-898
-2% -$183K 2.87% 7
2025
Q2
$9.54M Buy
51,372
+29
+0.1% +$5.39K 2.56% 10
2025
Q1
$10.8M Sell
51,343
-1,616
-3% -$314K 2.99% 8
2024
Q4
$9.41M Sell
52,959
-393
-0.7% -$72.3K 2.58% 10
2024
Q3
$10.5M Buy
53,352
+574
+1% +$107K 2.84% 8
2024
Q2
$9.05M Sell
52,778
-552
-1% -$91.4K 2.66% 9
2024
Q1
$9.71M Sell
53,330
-934
-2% -$161K 2.74% 8
2023
Q4
$8.41M Sell
54,264
-1,185
-2% -$173K 2.55% 9
2023
Q3
$8.27M Sell
55,449
-330
-0.6% -$48.4K 2.66% 10
2023
Q2
$7.52M Sell
55,779
-528
-0.9% -$77.4K 2.28% 13
2023
Q1
$8.97M Sell
56,307
-1,145
-2% -$175K 2.75% 8
2022
Q4
$9.28M Sell
57,452
-2,653
-4% -$407K 2.85% 9
2022
Q3
$8.07M Sell
60,105
-2,198
-4% -$315K 2.63% 11
2022
Q2
$9.54M Sell
62,303
-623
-1% -$95.2K 2.84% 8
2022
Q1
$10.2M Sell
62,926
-2,262
-3% -$329K 2.7% 8
2021
Q4
$8.83M Sell
65,188
-923
-1% -$109K 2.26% 15
2021
Q3
$7.13M Buy
66,111
+2,175
+3% +$249K 1.98% 16
2021
Q2
$7.2M Buy
63,936
+936
+1% +$105K 2.06% 17
2021
Q1
$6.82M Buy
63,000
+460
+0.7% +$49.2K 2.02% 20
2020
Q4
$6.7M Sell
62,540
-1,587
-2% -$153K 2.11% 18
2020
Q3
$5.62M Buy
64,127
+97
+0.2% +$9.13K 1.95% 21
2020
Q2
$6.29M Buy
64,030
+877
+1% +$77.2K 2.3% 17
2020
Q1
$4.81M Buy
63,153
+1,105
+2% +$94.1K 1.96% 21
2019
Q4
$5.49M Sell
62,048
-25
-0% -$2.08K 1.79% 25
2019
Q3
$4.7M Buy
62,073
+2,364
+4% +$162K 1.64% 26
2019
Q2
$4.34M Buy
59,709
+1,855
+3% +$146K 1.55% 29
2019
Q1
$4.66M Buy
57,854
+1,240
+2% +$101K 1.69% 25
2018
Q4
$5.22M Buy
56,614
+1,070
+2% +$94.1K 2.11% 19
2018
Q3
$5.25M Sell
55,544
-690
-1% -$65.4K 1.9% 24
2018
Q2
$5.21M Sell
56,234
-2,716
-5% -$265K 2% 21
2018
Q1
$5.58M Sell
58,950
-2,657
-4% -$292K 2.15% 19
2017
Q4
$5.96M Sell
61,607
-8,143
-12% -$767K 2.22% 19
2017
Q3
$6.2M Sell
69,750
-2,968
-4% -$226K 2.31% 16
2017
Q2
$5.27M Sell
72,718
-3,020
-4% -$203K 2% 20
2017
Q1
$4.93M Sell
75,738
-155
-0.2% -$9.74K 1.81% 24
2016
Q4
$4.75M Buy
75,893
+194
+0.3% +$11.8K 1.77% 23
2016
Q3
$4.77M Buy
75,699
+110
+0.1% +$7.12K 1.81% 21
2016
Q2
$4.68M Buy
75,589
+100
+0.1% +$6.09K 1.74% 24
2016
Q1
$4.31M Buy
75,489
+8,208
+12% +$457K 1.55% 26
2015
Q4
$3.99M Buy
67,281
+350
+0.5% +$20.2K 1.53% 28
2015
Q3
$3.64M Sell
66,931
-503
-0.7% -$32.7K 1.48% 31
2015
Q2
$4.53M Buy
67,434
+216
+0.3% +$14.1K 1.73% 25
2015
Q1
$3.94M Buy
67,218
+1,004
+2% +$60.7K 1.49% 30
2014
Q4
$4.33M Sell
66,214
-2,200
-3% -$139K 1.64% 26
2014
Q3
$3.95M Sell
68,414
-4,455
-6% -$247K 1.58% 27
2014
Q2
$4.11M Sell
72,869
-1,110
-2% -$58.2K 1.59% 27
2014
Q1
$3.8M Sell
73,979
-1,400
-2% -$70.8K 1.5% 28
2013
Q4
$3.98M Sell
75,379
-4,495
-6% -$221K 1.56% 28
2013
Q3
$3.57M Sell
79,874
-2,150
-3% -$95.3K 1.5% 28
2013
Q2
$3.39M Buy
+82,024
New +$3.59M 1.46% 30

Other funds holding ABBV

Monarch Capital Management's ABBV Position: Q2 2026 in Review

Monarch Capital Management increased its AbbVie (ABBV) stake by 0.56% in Q2 2026, buying an estimated $59.2K and bringing the position to 49,047 shares worth $12.3M. The position accounts for 2.83% of the portfolio, ranked #8.

Monarch Capital Management first reported a position in ABBV in Q2 2013 and has held it in 53 quarters since. 2,121 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Monarch Capital Management held 49,047 shares of AbbVie worth $12.3M as of Q2 2026.
  • Monarch Capital Management bought 275 AbbVie shares in Q2 2026, an estimated $59.2K.
  • AbbVie made up 2.83% of Monarch Capital Management's portfolio in Q2 2026, its #8 holding.
  • Monarch Capital Management first reported a position in AbbVie in Q2 2013 and has held it in 53 quarters since.
  • 2,121 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Monarch Capital Management's 13F filing for Q2 2026, filed 22 Jul 2026.